Advertisement
U.S. markets close in 2 hours 46 minutes
  • S&P 500

    4,594.40
    +8.81 (+0.19%)
     
  • Dow 30

    36,193.29
    +75.91 (+0.21%)
     
  • Nasdaq

    14,376.09
    +36.10 (+0.25%)
     
  • Russell 2000

    1,872.49
    +4.24 (+0.23%)
     
  • Crude Oil

    70.76
    +1.42 (+2.05%)
     
  • Gold

    2,013.10
    -33.30 (-1.63%)
     
  • Silver

    23.27
    -0.78 (-3.26%)
     
  • EUR/USD

    1.0758
    -0.0039 (-0.37%)
     
  • 10-Yr Bond

    4.2390
    +0.1100 (+2.66%)
     
  • GBP/USD

    1.2546
    -0.0047 (-0.38%)
     
  • USD/JPY

    144.8550
    +0.6640 (+0.46%)
     
  • Bitcoin USD

    43,882.03
    +496.62 (+1.14%)
     
  • CMC Crypto 200

    905.31
    +8.60 (+0.96%)
     
  • FTSE 100

    7,554.47
    +40.75 (+0.54%)
     
  • Nikkei 225

    32,307.86
    -550.45 (-1.68%)
     

Biogen halts trial of its Alzheimer’s drug Aducanumab

Biogen decided to end its phase 3 trial of its Alzheimer’s drug Aducanumab. Heritage Capital LLC President Paul Schatz and Yahoo Finance’s Brian Sozzi, Scott Gamm and Alexis Christoforous break down the impact on the company.

Advertisement